Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada. Cardiome Pharma Corp., a life sciences company, focuses on developing drugs to treat or prevent cardiovascular diseases. Its product Vernakalant (iv), which has completed Phase III (ACT 4) and in Phase III (European Comparator) trial is used for the treatment of atrial fibrillation; Vernakalant (oral) that has completed Phase IIa Pilot and Phase IIb study is used for atrial fibrillation; GED-aPC, an ongoing Phase I study product for multiple disease states; and Artesian Programs, which is in pre-clinical studies to attenuate the deleterious effects of the excessive neurohormonal activation that occurs in diseases of cardiac dysfunction.

EpiCept has made leukemia remission its entire mission. Its lead cancer drug candidate, Ceplene, is designed for use in adult patients who have had a complete remission from acute myeloid leukemia, but who are still at risk for relapse. It has been approved for use, along with interleukin-2, as a remission maintenance therapy in the EU, and it is awaiting approval in the US. The company's pipeline includes other cancer candidates, as well as topical analgesics for both acute and chronic pain. However, EpiCept has put all drug-discovery work on the back burner to focus on bringing Ceplene to market.

Premier Research Group, Ltd. was founded in 2002 and is based in Wokingham, United Kingdom. Premier Research Group, Ltd., a contract research organization, provides clinical trial management and information services to the pharmaceutical and biotechnology industries in Europe, Asia, Africa, Australia, Latin America, and North America. The company focuses its research and development program on enhancing software systems used to support its clinical trials management and information services. Its services include dedicated clinical sites, medical and safety management, medical writing, data management, biostatistics, interactive voice response systems, regulatory affairs, and quality assurance. The company conducts its clinical research in the areas of infectious diseases, oncology, pediatrics, analgesia, and CNS. The company was formerly known as CRC Development Limited and changed its name to Premier Research Group, Ltd. in November, 2004.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Manhattan Pharmaceuticals, Inc. company was founded in 2001 and is based in New York, New York. Manhattan Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of pharmaceutical therapies in the United States. Its product candidates under development include Hedrin, a novel, non-insecticide treatment for pediculosis; and Topical PTH (1-34) for the treatment of psoriasis. Manhattan Pharmaceuticals has a joint venture agreement with Nordic Biotech Advisors ApS to develop and commercialize Hedrin.

The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California. Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing its product candidates principally for use in the hospital setting. The Company has in-licensed rights to two late stage product candidates, Acetavance a intravenous formulation of acetaminophen and Omigard (omiganan pentahydrochloride) 1% aqueous gel. It has in-licensed the exclusive United States and Canadian rights to Acetavance, that is marketed in Europe for the treatment of acute pain and fever by Bristol-Myers Squibb Company (BMS). The Company has also in-licensed the rights to commercialize Omigard in North American and Europe.

Takeda San Diego develops high-throughput protein crystallography systems used to speed up the drug discovery process. The company's technology can detect the three-dimensional shape of proteins, an important step in determining how a drug can be attached to a protein to produce a therapeutic effect. The US biotech developer is one of Japanese drug maker Takeda's main research and development facilities. The subsidiary's drug discovery know-how is being used to develop new therapies for metabolic diseases such as diabetes, cancer, and inflammatory conditions.

Peregrine Pharmaceuticals, Inc. company was founded in 1981 and is based in Tustin, California. Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and manufacture of monoclonal antibodies for the treatment of cancer and viral infections. The company develops clinical programs with its novel compounds bavituximab and Cotara, which are the clinical candidates under its anti-phosphatidylserine therapeutics and tumor necrosis therapy platforms. Its pipeline products comprise Bavituximab Plus Docetaxel, and Bavituximab plus carboplatin and paclitaxel, which are Phase II clinical trial products for treating advanced breast cancer patients; and Bavituximab plus carboplatin and paclitaxel, a Phase II clinical trial product for the treatment of non-small cell lung cancer, as well as Bavituximab, which is in Phase I monotherapy repeat dose safety study for treating solid tumor cancers, and in Phase Ib repeat dose safety study for the treatment of chronic hepatitis C virus infection co-infected with HIV. In addition, its pipeline products include Cotara, a product in Phase II, as well as a dosimetry and dose confirmation study for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. Further, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture. Further, it provides services in support of Peregrine's product pipeline, including manufacture and scale-up of pre-clinical and clinical drug supplies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.